title: Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma.
abstract: Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Adriano M
authors.initials: AM
authors.lastname: Pellicelli
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: D'Ambrosio
authors.affiliation: Department of Hematology Istituti Fisoterapici Ospedalieri, Italy.
authors.forename: Maria L
authors.initials: ML
authors.lastname: Dessanti
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Villani
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Fondacaro
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Miglioresi
authors.affiliation: Department of Pathology, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Lucia R
authors.initials: LR
authors.lastname: Grillo
authors.affiliation: Liver Unit, Azienda Ospedaliera San Camillo Forlanini, Italy.
authors.forename: Arnaldo
authors.initials: A
authors.lastname: Andreoli
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D002779:Cholestasis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D016174:Hepacivirus / Q000187:drug effects* / Q000472:pathogenicity; D006526:Hepatitis C / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D000069283:Rituximab